Source/Disclosures
Source: Healio Coverage
July 09, 2020
1 min read
Save

Top in hem/onc: Repurposing cancer drugs for COVID-19, Phesgo approval

Source/Disclosures
Source: Healio Coverage
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Many anticancer drugs — including BTK inhibitors, JAK inhibitors, immunomodulatory drugs, and more — are being investigated as potential COVID-19 treatments. An overview of these investigations was the top story in hematology/oncology last week.

Another top story was about the FDA approval of Phesgo (Genentech), an at-home treatment regimen for adults with HER2-positive breast cancer.

FDA approval
The FDA recently approved Phesgo for the treatment of adults with HER2-positive breast cancer.
Source: Adobe Stock.

Read these and more top stories in hematology/oncology below:

Cancer drugs’ targeted, anti-inflammatory effects support repurposing for COVID-19

Jai N. Patel, PharmD, BCOP, CPP, chair of cancer pharmacology and associate professor in the division of hematology/oncology at Levine Cancer Institute at Atrium Health, provides an overview of anticancer drugs that are being investigated as potential molecules for drug repurposing against COVID-19 given their targeted and anti-inflammatory effects. Read more.

FDA approves Phesgo, at-home treatment regimen for breast cancer

The FDA recently approved Phesgo, the combination of pertuzumab (Perjeta, Genentech), trastuzumab (Herceptin, Genentech) and hyaluronidase-zzxf, for the treatment of adults with HER2-positive breast cancer. Read more.

ASH to develop 'living guidelines' for anticoagulant use among patients with COVID-19

Abnormalities in blood clotting have been linked to increased mortality risk among patients with COVID-19. Read more.

‘A call to arms’: Addressing the undertreatment of advanced bladder cancer

For decades, the 5-year survival rate for patients with advanced bladder cancer has remained at about 35%. Read more.

FDA approves Keytruda as first-line treatment for colorectal cancer subtype

The FDA approved pembrolizumab (Keytruda, Merck) for first-line treatment of patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient colorectal cancer. Read more.